EGFR and breast carcinoma: On the basis of the aforementioned findings, 2-(quinoline-4-carbonyl)hydrazide-3-(4-nitrophenyl)acrylamide 6h could be considered as EGFR-TK inhibitor and fruitful clue for the development of novel antitumor agents against breast carcinoma.